Clinical Trials Logo
  1. Home
  2. Prostate Cancer Metastatic
  3. NCT05078151

Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer — iPROMET  

Prostate Cancer Metastatic Clinical Trial

Official title:
A Study to Clinically Qualify Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) in Patients With Metastatic Castration Resistant Prostate Carcinoma With Bone Metastases

Clinical Trial Summary

The skeleton is the most frequent organ of distal metastases in prostate cancer, often representing the only site of metastatic disease. Still, assessment of response and progression to therapies in bone metastases remains a major unmet need, to aid treatment switch decisions, detecting primary/secondary resistance and to optimize drug development. The currently used standard imaging techniques, computed tomography (CT) and bone scintigraphy (BS), do not depict the true extent of bone metastases and are suboptimal in capturing biological changes occurring in response to treatment. This results in treatment switch decisions too often being based on PSA changes, which is neither a surrogate of survival, nor an optimal response biomarker.Diffusion-weighted imaging (DWI) is a functional magnetic resonance imaging (MRI) technique that studies the movement of water molecules within a tissue and provides valuable information about the tissue microstructure and cellularity. Whole body MRI with DWI is highly accurate for bone metastases detection, outperforming the standard CT and BS and other imaging techniques when assessing bone metastases. The investigators hypothesise that DWI changes are a response biomarker in bone metastases from metastatic castration resistant prostate cancer (mCRPC); these DWI changes can be detected as early as after 4 weeks of systemic treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05078151
Study type Interventional
Source Vall d'Hebron Institute of Oncology
Contact
Status Recruiting
Phase N/A
Start date September 1, 2018
Completion date September 1, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Suspended NCT05361915 - Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05067140 - A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer Phase 1/Phase 2
Completed NCT03646162 - Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer Phase 2
Active, not recruiting NCT03413995 - Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Phase 2
Not yet recruiting NCT06461689 - Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
Recruiting NCT03507595 - Evaluation of the Metastasis and Recurrence of Prostate Cancer
Completed NCT03362359 - Ga-68-PSMA-11 in High-risk Prostate Cancer Phase 1/Phase 2
Recruiting NCT04116775 - Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Phase 2
Completed NCT03223727 - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
Recruiting NCT04983095 - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase 3
Recruiting NCT04086290 - National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients Phase 1/Phase 2
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04983628 - Molecular Profiling in Prostate Cancer
Active, not recruiting NCT03414437 - Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
Completed NCT02485691 - Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Phase 4
Completed NCT03693742 - MSG Use With 18F-DCFPyL PET/CT Imaging N/A
Completed NCT01322490 - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Phase 3
Completed NCT03739684 - Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Phase 3
Recruiting NCT05655715 - Checkpoint Inhibitors and SBRT for mCRPC Phase 2